Isabelle Isnardi, PhD

Novartis
Basel, Switzerland

B cell immunologist.

Presentation(s):

• 0903: Ianalumab‘s dual mode of action: targeting B cells through enhanced B cell depletion and blockade of B cell-activating factor receptor signaling

  Monday, October 27, 2025
  10:30 AM - 12:30 PM Central Time

  Disclosure(s): Novartis: Employee (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing)